Aratana Therapeutics Inc. buy klostergang
Zusammenfassung
Diese Einschätzung wurde am 06.03.19 mit einem Endkurs von 3,63 € beendet. Herbe Verluste von -39,91 % verzeichnete die BUY Einschätzung von klostergang. klostergang hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Aratana Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | 1,40 % | -0,70 % | 15,47 % | 15,91 % |
| iShares Nasdaq 100 | 2,29 % | 7,50 % | 34,75 % | 53,47 % |
| iShares Nikkei 225® | 1,62 % | 2,77 % | 11,44 % | 8,19 % |
| iShares S&P 500 | 0,66 % | 4,28 % | 26,78 % | 45,32 % |
Kommentare von klostergang zu dieser Einschätzung
In der Diskussion Aratana Therapeutics Inc. diskutieren
Aranta is a long term growth play in a growing market for therapeutics for dogs and cats
Product Portfolio:
The company is well positioned to take advantage of the secular trend of consistently growing spending on dogs and cats. The company has three approved and launched products in its portfolio now.
Galliprant:
This compound is approved for the control of pain and inflammation associated with osteoarthritis in dogs. It is marketed and distributed by Elanco, a division of Eli Lilly.
The company receives a variety of milestones and royalties from Elanco through a collaboration deal around Galliprant.
Nocita:
This is a wholly owned compound approved as a post-operative anesthetic for cranial cruciate ligament surgery in dogs.
Entyce:
Another wholly owned compound approved to trigger appetite stimulation in dogs. Entyce should
find a receptive market. According to recent surveys, two thirds of veterinarians are not satisfied with current products on the market to treat this condition.